NEW YORK, NY, Sept. 13 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Philip Gould as a Member Designate of its Scientific Advisory Board (SAB).
Dr. Gould will contribute his career experience in multinational blue chip drug discovery companies as well as his drug patenting experience to GENova's business of identifying, evaluating and developing pioneering research drugs
Aaron Whiteman, CEO of GENova, says, "Mr. Gould's esteemed position as an international business leader in the healthcare and drug development sectors is an asset to GENova."
About Dr. Philip Gould
Mr. Gould is presently the Chief Business Officer of the Liverpool School of Tropical Medicine, the first institution of its kind dedicated to research in tropical medicine. He also maintains his position as Founder and CEO of Jadara Pharma Ltd, a profitable healthcare business consultancy with contracts in strategic business planning, fund raising, patent litigation, strategic product development, spin out portfolio management and investor support to trade sale or IPO. Previously, he was CEO of Provalis plc, a pharmaceutical and medical diagnostics company. Other positions have included Principle Research Scientist and Senior Manager of Pharmaceutical Development for Pfizer, and Head of New Product Development for GlaxoSmithKline.
He has produced over 20 publications as a primary author, and has presented 25 papers at seminars on a variety of both technical and managerial subjects, and has been named as an inventor on 4 patents. He holds a Ph.D in Physical Chemistry.
About GENova Biotherapeutics Inc.
GENova is positioning itself as the world's leading bioscience company in the development an
|SOURCE GENova Biotherapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved